NCT05083065View on ClinicalTrials.gov

Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine

CompletedOBSERVATIONAL

Enrollment

369

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

October 10, 2021

Study Completion Date

December 30, 2021

Conditions

COVID-19VaccineMenstrual IrregularityMenopausal Bleeding

Interventions

BIOLOGICAL

Covid-19 vaccine

"* First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~* First dose or complete cycle of Spikevax (Moderna) vaccine~* First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~* Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~* Janssen (Johnson \& Johnson) vaccine (single dose)"

Trial Locations (1)

Unknown

University of Insubria, Varese

All Listed Sponsors

lead

Università degli Studi dell'Insubria

OTHER

NCT05083065 - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine | Biotech Hunter | Biotech Hunter